Amplex AB has obtained all approvals from authorities for the offer to the shareholders and warrantholders of ADDvise Group AB (publ) and declares the offer unconditional

Amplex AB has received required regulatory clearances (including from the Swedish Inspectorate of Strategic Products), waived the acceptance-level condition and declared its public offer for ADDvise Group AB unconditional. The offer was revised from SEK 1.65 to SEK 1.72 per Class A/B share (warrants increased from SEK 0.49 to SEK 0.52), and Amplex now controls >59% of shares and >66% of votes following conditional acquisitions representing ~21.11% of capital; settlement for tenders is expected around 30 January 2026 with the acceptance period ending 23 January 2026. This secures effective control and paves the way for ADDvise to be taken private, materially impacting remaining minority holders and near-term trading in ADDvise securities.

Analysis

Market structure: Amplex’s unconditional offer crystallizes a firm buyout price (SEK 1.72/share, SEK 0.52/warrant) and will likely compress ADDvise’s free float by >59% immediately and possibly >90% if further purchases occur. Direct winners: Amplex (control), selling shareholders capturing a cash premium; losers: remaining minority holders facing illiquidity and potential squeeze‑out. Broader small‑cap Swedish life‑science traded on First North will see slightly reduced liquidity and potential takeover arbitrage flows in the near term.

Risk assessment: Near‑term regulatory risk is low—strategic products clearance already received—so tail risks center on legal challenges, foreign-holder tender invalidations, or failure of settlement mechanics around 30 Jan 2026. Time horizons: immediate (days) — spread capture to 1.72; short (weeks) — potential negotiated top‑ups or secondary purchases; long (quarters) — private restructuring or asset sales that could reset enterprise value. Hidden dependencies include cross‑border holder exclusion (several jurisdictions blocked) which may leave actionable arbitrage opportunities and tax/withholding complexities for U.S. holders.

Trade implications: Primary direct play is takeover arbitrage: buy ADDvise (Nasdaq First North) when market price is >=5–7% below 1.72 and size 1–3% portfolio, target settlement (~30 Jan 2026) exit at 1.72 or earlier. If borrow is available, consider shorting residual float post‑settlement if Amplex signals squeeze‑out intentions; hedge sector beta with a short basket of First North life‑science names. Options: where available, buy Feb 2026 puts (strike ~1.40) to cap downside for any long exposure and sell short‑dated covered calls if holding to tender.

Contrarian angle: Consensus views likely underweight the probability Amplex will sweeten post‑close; historical Swedish small‑cap takeovers sometimes see opportunistic negotiated purchases above the offer to secure >90% control — watch for incremental buy‑orders at small premiums (5–15%). The market may underprice logistics/settlement risk (operational or withholding tax delays); if ADDvise trades >2% below 1.72 in the next 5 trading days, that is a mispricing to exploit, not a structural signal.

Key Decisions for Investors

• Establish a takeover‑arbitrage long in ADDvise (Nasdaq First North) sized 1–3% of portfolio if market price <= SEK 1.62 (>=~6% spread to SEK 1.72). Tender if within acceptance window; target exit at settlement (~30 Jan 2026) or upon price converging to SEK 1.72.
• If unable to purchase or borrow ADDvise, buy Feb 2026 put options (strike ~SEK 1.40) sized to protect up to 40% of notional exposure when taking any long; allocate no more than 0.5% portfolio to option premia given low liquidity.
• Post‑settlement (within 30 days), monitor Amplex stake disclosures: if Amplex signals purchases to reach >90% threshold, maintain a small long and plan to hold for potential squeeze‑out at or above SEK 1.72; if no activity and liquidity collapses, exit remaining exposure within 10 trading days to avoid illiquidity risk.
• Relative‑value hedge: pair long ADDvise with a short position in a small‑cap First North life‑science basket equal delta exposure (size hedge to neutralize sector risk); reduce net exposure if the sector index falls >5% in a week.